Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (194)	1/8/1998 4:37:00 PM
From: Don W Stone	Respond to of 507

Goldman Sachs, UBS Securities, Montgomery securities would be a good start. Also i just heard that Donaldson Lufkin is now following the stock and likes it alot. I heard they picked it as one of the best performing biotechs for '98. Hey , go for it. Your timing couldn't be better. :-} I f you want to know more give me a call.

To: David S. who wrote (194)	1/8/1998 10:25:00 PM
From: Don W Stone	Read Replies (1) \| Respond to of 507

David: You do know that FDA approval is indeed imminent so one shouldn't drag one's feet. I said your timing couldn't be better because right now NVX is about where it was exactly a year ago.That is in the market, not the Company. It has been a whole year of waiting for the stockholder. Meantime the company has been going ahead with business as usual. As a developement stage company they can do that so while they are busy adding value Wall street stews because the value lacks visibility W.S. is really myopic with EPS. Well that is about to change. '98 should be a very good year for NVX and '99 should be even better. My guess is the Company could have a new product to market about every 18-24 months for the foreseeable future ( next 5 years). Keep in touch. e-mail me if i can be of help.